about
Plant-based solutions for veterinary immunotherapeutics and prophylacticsChallenges in mucosal HIV vaccine development: lessons from non-human primate modelsSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusProtection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection.Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in miceOral bacillus Calmette-Guérin vaccine against tuberculosis: why not?Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.Exploiting fungal cell wall components in vaccinesBolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineDifferent routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3Intranasal formulations: promising strategy to deliver vaccines.Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.Intranasal delivery of nanoparticle-based vaccines.Development of a Novel Anti-Adhesive Vaccine Against Pseudomonasaeruginosa Targeting the C-terminal Disulfide Loop of the Pilin Protein.Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin.Patient-centered drug delivery and its potential applications for unmet medical needs.A Review of DNA Vaccines Against Influenza
P2860
Q27000876-A1D9519A-71C0-4FD7-8EF3-0AF549A12260Q27022152-410EF86E-6D49-4011-AD7D-C83CBEC5EBFAQ28067143-51BBA7BA-89AE-4922-9DF6-61A714621256Q33562716-E602B59B-CC16-4DC5-AE89-D51B4D927EDCQ34257517-D34FFCDE-D619-4C45-9F5A-F1D18AEAE14FQ34548500-A84303B3-330B-42DE-8AC7-00AD20902B94Q35080048-02807227-B3ED-4994-AE82-F44E1D53315BQ35085200-AB58BB38-66DE-4B20-9357-42C4EBB5BEC5Q35917496-A51372CC-C827-43AD-8F87-01C67F300009Q37594124-6712108C-0D4D-4937-B028-F14B22203700Q38223050-09D44423-10AC-4938-8705-8EC70E2CC1F4Q38665950-924F8BFA-C40D-43D9-B332-E4DD9F532A44Q38999003-384DA93B-A770-4B6C-8C5F-611129839352Q39113247-10C1D816-FB5F-4EDC-9CFC-A1286B43278CQ40054483-48138EBB-06C8-4661-A987-5E8649D606B6Q42000415-30617492-57C4-4942-81B4-71A41213221AQ53099408-19281B6A-310F-40E2-AFFD-4C021F3D192FQ57094261-FEFFAC04-3B18-408B-85C8-FD353F637CDF
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Strategies for intranasal delivery of vaccines
@ast
Strategies for intranasal delivery of vaccines
@en
type
label
Strategies for intranasal delivery of vaccines
@ast
Strategies for intranasal delivery of vaccines
@en
prefLabel
Strategies for intranasal delivery of vaccines
@ast
Strategies for intranasal delivery of vaccines
@en
P2093
P2860
P1476
Strategies for intranasal delivery of vaccines
@en
P2093
Istvan Toth
Mehfuz Zaman
Saranya Chandrudu
P2860
P2888
P304
P356
10.1007/S13346-012-0085-Z
P577
2012-07-12T00:00:00Z